FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
7.01.2018
0:00
NaN:NaN:NaN
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.
Released on December 21, 2017
Więcej odcinków z kanału "FDA Drug Information Updates"
Nie przegap odcinka z kanału “FDA Drug Information Updates”! Subskrybuj bezpłatnie w aplikacji GetPodcast.